

PANCURONIUM

| | |
|---------------------------------|---|
| PRESENTATION: | Ampoules containing 4mg/2ml |
| INDICATION: | Muscle relaxation. Non-depolarising neuromuscular blocking agent with a long duration of action. |
| DOSE AND ADMINISTRATION: | Initial dose: 60microgram/kg by IV injection over 3-5 minutes (Note please use ideal body weight). Additional doses of 20-30microgram/kg can be given 1 - 1 ½ hourly if required. Ideally administer via CVC or a large peripheral vein due to risk of venous irritation caused by low pH. Can be given undiluted or in sodium chloride 0.9% or glucose 5% for ease of administration. |
| CONCENTRATION: | 2mg/ml |
| STABILITY: | Physically and chemically stable for 24hours. |
| ADDITIONAL INFORMATION: | In common with all neuromuscular blocking agents, monitoring of neuromuscular function using train-of-four peripheral nerve stimulation, is recommended during the use of pancuronium in order to individualise dosage requirements. |

References

1. Pancuronium Bromide, Summary of Product Characteristics. Manufactured by Hospira UK Ltd. <https://www.medicines.org.uk/emc/product/3793/smpc> Accessed May 2020
2. Pancuronium Bromide, Injectable Medicines Guide <https://medusa.wales.nhs.uk/IVGuideDisplay.asp> Accessed May 2020
3. Pancuronium Bromide, Storage and Stability, Trissel, Micromedex. Accessed via Knowledge Network, May 2020

| | |
|---|-------------------------------|
| Title: Pancuronium | |
| ID: | Authors: Mairi Cromarty |
| Category: | Document Version: 1.0 |
| Status Draft/Final: FINAL | Review Date: July 2022 |
| Authoriser: Lothian Critical Care QIT Editorial Board | Authorisation Date: July 2020 |
| Date added to Intranet: 01/07/20 | |
| Key Words | |
| Comments | |